By Jake Siegel and Brian Finrow
Today we announced several milestones in the clinical development of LMN-201, Lumen’s orally delivered biologic cocktail to prevent C. difficile infection (CDI). The big headline: the FDA has greenlit Phase 2 studies of LMN-201. Soon we will start enrolling hundreds of newly diagnosed CDI patients across multiple sites in the U.S. (Physicians interested in participating should contact Lumen’s clinical operations team at trials@lumen.bio.)
It’s an exciting moment for our company, and an exciting opportunity to help patients suffering from CDI. Nearly half a million people are diagnosed with the disease each year in the U.S. alone. A distressingly high number of these patients live with the specter of recurrence, and they have very few options to prevent the disease’s return. The experience can be horrific: a shocking 7% of CDI patients died within 12 weeks of diagnosis in one particularly well-done study. Worryingly, there are signs that antibiotic resistant strains of C. difficile are spreading in the U.S., compounding the risks to us all.
